Advertisement
Indian
India’s Zydus Cadila seeks approval for its 3-dose COVID vaccine
Zydus said the efficacy result is based on an interim analysis of a late-stage trial of more than 28,000 volunteers nationwide, including nearly 1,000 subjects in the age group of 12 to 18.
Immunogenicity data for the adolescent children subset will be submitted in the next four to six weeks, Patel said.
Not much data on Delta plus variant to suggest it’s more infectious, causes more deaths: Delhi AIIMS director
‘Submit results on Covavax adult trials first’: Govt panel to SII on Covid-19 vaccine trials for children
LIC’s mega IPO gains momentum, Govt notifies amendments in LIC Act
According to one of the 27 proposed amendments, the central government will hold at least 75 per cent in LIC for the first five years post the IPO, and subsequently hold at least 51 per cent at all times after five years of the listing.
But from today, the policy holders will get 90 per cent of surplus generated by the corporation while the rest as dividends will go to the government and other shareholders who will be investing in the LIC through its Initial Public Offering(IPO).
International
U.S. warns merchant ships of possible Iranian attacks; cleric threatens U.S. fleet
G7 countries to simulate cross-border cyber attack next month: France
Curv Partners with Munich Re to Commodify Digital Asset Insurance for Institutional Customers
“The novel cryptographic methods deployed in Curv’s Institutional Digital Asset Wallet Service reduce the risks associated with holding digital assets.Their approach enables us to underwrite a policy that covers customer-controlled wallets in Internet-connected settings. ,” said Ali Kumcu, Head of Cyber Innovation and Services, of Munich Re.
Munich Re appoints Linus Phoon CEO for Singapore & Southeast Asia
Briefs
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Events
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Advertisement
Articles
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Features
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Data
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Interviews
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Facts
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
